Related Experiment Video

Updated: Jun 23, 2026

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease
05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

NKG2D as a molecular link between epithelial stress and immune activation in Crohn's disease: therapeutic

Alexander V Blagov1, Marina D Sazonova2, Anastasia I Ryzhkova3

  • 1Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Moscow, Russian Federation. al.blagov2014@gmail.com.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|June 20, 2026
PubMed

Insights

Targeting the NKG2D receptor shows promise for treating Crohn's disease (CD) by reducing inflammation and improving outcomes. Further research is needed to overcome challenges and optimize therapies for this chronic condition.

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Crohn's disease (CD) is a chronic inflammatory bowel disorder with unmet therapeutic needs.
  • Immune dysregulation and epithelial barrier defects are key features of CD pathogenesis.
  • The NKG2D receptor and its ligands play a role in intestinal inflammation.

Purpose of the Study:

  • To investigate the role of the NKG2D receptor pathway in Crohn's disease.
  • To evaluate the therapeutic potential of targeting NKG2D in preclinical models and clinical trials.
  • To identify future directions for NKG2D-based therapies in CD.

Main Methods:

  • Analysis of NKG2D ligand expression in intestinal epithelial cells.
  • Preclinical studies using colitis models.
  • Clinical trials with anti-NKG2D monoclonal antibodies.

Main Results:

  • Upregulated NKG2D ligands on intestinal cells promote inflammation and epithelial injury in CD.
  • Anti-NKG2D therapy reduced disease activity and improved histology in preclinical models.
  • Clinical trials showed remission induction in moderate-to-severe CD patients treated with anti-NKG2D antibodies.

Conclusions:

  • NKG2D signaling is a critical driver of inflammation and tissue damage in Crohn's disease.
  • Targeting NKG2D represents a promising therapeutic strategy for CD.
  • Future strategies include biomarker selection, combination therapies, and novel biologics.

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...